Keywords
PCSK9MedicineKexinTolerabilityProprotein convertaseLDL receptorInternal medicinePharmacologyLipoproteinEvolocumabEndocrinologyCholesterolAdverse effect
Affiliated Institutions
Related Publications
Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin
Twenty-two years ago, the landmark 4S trial demonstrated that statin therapy could reduce rates of recurrent myocardial infarction, stroke, and cardiovascular death among second...
Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])
This study compared the relative efficacy of a once-daily niacin extended-release (ER)/lovastatin fixed-dose combination with standard doses of atorvastatin or simvastatin, with...
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)
The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin acros...
Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study
Abstract This multicenter, double‐blind, placebo‐controlled study was conducted to evaluate dose‐response effects and safety of once‐daily administration of pravastatin, a new i...
The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors
A bstract : Raloxifene, a selective estrogen receptor modulator, favorably alters several markers of cardiovascular risk in healthy postmenopausal women. While many of its effec...
Publication Info
- Year
- 2015
- Type
- review
- Volume
- 65
- Issue
- 24
- Pages
- 2638-2651
- Citations
- 191
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
191
OpenAlex
Cite This
Robert P. Giugliano,
Marc S. Sabatine
(2015).
Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?.
Journal of the American College of Cardiology
, 65
(24)
, 2638-2651.
https://doi.org/10.1016/j.jacc.2015.05.001
Identifiers
- DOI
- 10.1016/j.jacc.2015.05.001